今年以来，三特异性抗体新药的研发也不断迎来进展。根据中国国家药监局药品审评中心（CDE）官网以及公开资料，2024年以来，有至少10款三抗1类新药在中国获批IND，进入临床研究阶段。这些新药拟开发的适应症包括恶性实体瘤、血液系统肿瘤以及自身免疫性疾病 ...

医保局发文，2024 年国谈将在本周日（10 月 27 日）正式开始。本次共有 162 个通用名药品确认参加谈判/竞价。而相较于之前公布的通过形式审查的药品数量来看（392 个品种，Insight 数据库根据过初审名单统计），本次国谈专家审评通过率仅 ...

《科创板日报》10月29日讯（记者 郑炳巽）经过了第一天相对轻快的进程以及第二天胶着的苦战之后，2024国家医保谈判进入到第三天。 上午8点不到，《科创板日报》记者发现全国人大会议中心外面的已经聚集了很多人员。事实上，今天现场的气温大概11℃，明显 ...

Polatuzumab vedotin, created in collaboration with Seattle Genetics, (Bothell, Washington, United States) is composed of a CD79b-specific monoclonal antibody conjugated to a microtubule-disrupting ...

随着海外经验的逐渐丰富，恒瑞未来或不仅仅是出售产品。参考国际跨国药企（MNC）的发展经验，收购始终是企业壮大的一环。若恒瑞希望持续稳居 中国医药 行业的领军地位，资本市场的助力将不可或缺。

THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...

Wertz showed how the cytotoxic payload of a CD79b-targeted antibody-drug conjugate called polatuzumab vedotin works, in part, by promoting proteasome-mediated degradation of MCL-1, an anti ...

Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B-cells (an immune cell impacted in some types of non-Hodgkin ...

研究还发现，DHA 干预后，脾脏滤泡B细胞中MHCII分子表达下调；同时，滤泡B细胞中与B 细胞活化相关的关键分子（CD79a、CD79b 和 Ms4a1）的表达水平也 ...

To that end, Roche is hoping to pair Columvi with Polivy (polatuzumab vedotin), its CD79b-targeted antibody-drug conjugate (ADC), which was approved by the FDA for previously untreated DLBCL in ...

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma #782 oral presentation ...